News
Latest News
DateTitle of press release
22 May 2008Study results confirm T-SPOT®.TB is not affected by low CD4 count HIV infected subjects
(156k.pdf)
20 February 2008Study results demonstrate ability of T-SPOT®.TB to monitor declining response in subjects receiving anti-TB treatment
(149k.pdf)
29 October 2007Oxford Immunotec completes $40M financing
(152k.pdf)
09 October 2007Study results confirm T-SPOT®.TB is cost-effective in TB control programmes
(225k.pdf)
10 September 2007Study results suggest the utility of T-SPOT®.TB in monitoring treatment for latent TB infection (LTBI)
(226k.pdf)
10 August 2007Report highlights the reliability of T-SPOT®.TB following administration of the Tuberculin Skin Test.
(225k.pdf)
04 May 2007Oxford Immunotec Ltd wins Best Healthcare Innovation Award and recieves the additional accolade of Overall Winner of the Martin and Audrey Wood Enterprise Awards 2007
(40.7k .pdf)

Photograph of award winners - Peter Wrighton-Smith, CEO, is pictured second from right
(5.25MB)
19 April 2007Study results confirm utility of T-SPOT®.TB as a rapid rule out test for tuberculosis disease
(227k .pdf)
04 April 2007Oxford Immunotec Grants License over T-SPOT® technology to sanofi pasteur for human vaccine research
(226k .pdf)
28 March 2007Study results confirm superior efficacy of T-SPOT®.TB over QuantiFERON and the TST in detecting TB infection in HIV patients
(232k .pdf)
19 March 2007Oxford Immunotec Announces appointment of President – North America and filing for FDA approval for T-SPOT®.TB
(227k .pdf)
05 March 2007Study results support use of T-SPOT®.TB to monitor latent TB infection (226k .pdf)
02 August 2006Study results confirm superior performance of Oxford Immunotec Ltd's T-SPOT®.TB over other diagnostic tests for tuberculosis (47k .pdf)
26 July 2006Oxford Immunotec Strengthens Team with Two Strategic Board Appointments (35k .pdf)
26 June 2006Oxford Immunotec sponsors Doctors.net.uk and Masterclass Plus healthcare training programmes to support best practice guidelines for the diagnosis of TB (34k .pdf)
05 April 2006Study results confirm ability of T-SPOT.TB to detect tuberculosis disease in HIV infected patients (31k .pdf)
29 March 2006Study results confirm maintained performance of T-SPOT.TB in repeat testing environment (31k .pdf)
15 March 2006Study results confirm higher sensitivity of T-SPOT.TB in immunosuppressed patient groups (81k .pdf)
27 February 2006Oxford Immunotec announces further strengthening of Senior Management team (45.8k .pdf)
6 February 2006Oxford Immunotec's T-SPOT.TB is first test to demonstrate accurate diagnosis of latent TB in HIV patients (38k .pdf)
31 January 2006Oxford Immunotec Announces Launch of Second Generation Product Based on Co-Development with Millipore (78.6k .pdf)
27 January 2006UK Nurses and General Public Reject Introduction of 115-Year-Old Tuberculosis (TB) Test (52k .pdf)
24 January 2006Study Results Demonstrate Accuracy of T-SPOT.TB in Contact Tracing
4 November 2005Oxford Immunotec Wins Medical Futures Innovation Award (50k .pdf)
10 October 2005Oxford Immunotec appoints Chief Financial Officer (28k .pdf)
21 September 2005Millipore and Oxford Immunotec Co-develop Plates for Diagnosing and Monitoring Infections (80k .pdf)
3 August 2005Oxford Immunotec Closes £7M in Series B Financing (37k .pdf)
11 July 2005Oxford Immunotec Prevails in Core Patent Dispute with Cellestis and Sanofi-Pasteur (44k .pdf)
T-SPOT®and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
© 2006 Oxford Immunotec Ltd.